SCHEMBL872358

SCHEMBL872358

BrCC(CBr)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.48
SLC1A3 P43003 2/20 0.47
SLC1A2 P43004 2/20 0.47
SLC1A1 P43005 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
MEN1 O00255 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
IDO1 P14902 1/20 0.44
ALDH1A1 P00352 4/20 0.44
TRPA1 O75762 1/20 0.44
AGXT P21549 1/20 0.43
TDP1 Q9NUW8 2/20 0.41
SLC6A2 P23975 3/20 0.41
SLC6A3 Q01959 3/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9188228 0.88 IDO1 (0.36) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL11448991 0.88 TSHR (0.41) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL871423 0.88 TSHR (0.41) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL14754591 0.86 ALDH1A1 (0.40) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL27876875 0.85 PSMB5 (0.41) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL9187375 0.84 IDO1 (0.39) SLC1A3SLC1A2SLC1A1KMT2ACYP1A2
SCHEMBL2319770 0.84 ALDH1A1 (0.47) SLC1A3SLC1A2SLC1A1KMT2ACYP1A2
SCHEMBL18555483 0.83 TSHR (0.44) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL7011964 0.82 TSHR (0.48) TSHRSLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL11265351 0.78 RXRA (0.40) TSHRKMT2AALDH1A1TDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 US disclosed
US-12421251-B2 Cystic fibrosis transmembrane conductance regulator modulating agents VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-09-23 US disclosed
WO-2025076632-A1 COMPOUNDS AND USES THEREOF FIBROCOR THERAPEUTICS INC. (CA) 2025-04-17 WO disclosed
CN-112261970-B 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family zinc finger 2 (IKZF 2) dependent diseases 诺华股份有限公司 2025-02-07 CN disclosed
CN-119241499-A 3- (5-Hydroxy-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof 诺华股份有限公司 2025-01-03 CN disclosed
EP-2895488-B1 TRICYCLIC GYRASE INHIBITORS FOR USE AS ANTIBACTERIAL AGENTS MERCK SHARP & DOHME LLC (US) 2024-12-11 EP disclosed
CN-113905785-B Cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2024-07-19 CN disclosed
EP-4335498-A1 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS Vertex Pharmaceuticals Incorporated (US) 2024-03-13 EP disclosed
EP-4306111-A2 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF Novartis AG (CH) 2024-01-17 EP disclosed
EP-3946595-B1 CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS VERTEX PHARMA (US) 2023-11-15 EP disclosed
WO-2004099224-A1 CARBOPLATIN-TYPE PLATINUM (II) COMPLEXES UNIVERSITÄT REGENSBURG (DE) 2004-11-18 WO disclosed
US-6080750-A FOR PROPHYLAXIS AND TREATMENT OF DISEASES CAUSED BY INFECTION BY ROTAVIRUS NIPPON SHOJI KAISHA LTD. (JP) 2000-06-27 US disclosed
EP-0806418-A2 Novel pyrimidine compound and anti-rotavirus agent NIPPON SHOJI KAISHA, LIMITED (JP) 1997-11-12 EP disclosed
EP-0454270-B1 Catalyst compositions SHELL INT RESEARCH (NL) 1993-12-15 EP disclosed
US-5229343-A Polymerization process SHELL OIL COMPANY (US) 1993-07-20 US disclosed
US-5171832-A POLYMERIZATION OF CARBON MONOXIDE/OLEFIN WITH P BIDENTATE LIGAND HAVING (1) ALKOXY PHENYL P GROUP AND (2) MONOSUBSTITUTED DIVALENT BRIDGING GROUP SHELL OIL COMPANY (US) 1992-12-15 US disclosed
EP-0454270-A1 Catalyst compositions SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1991-10-30 EP disclosed
US-4360464-A Process for production of 1-aryloxy-aminopropane derivatives TEIKOKU HORMONE MFG. CO. LTD. (JP) 1982-11-23 US disclosed
EP-0045964-A1 Derivatives of 3-amino-1,2-propane diol CIBA-GEIGY AG (CH) 1982-02-17 EP disclosed
US-4018824-A ANTIULCER AND ADRENERGIC BLOCKING AGENTS TEIKOKU HORMONE MFG. CO., LTD. (JA) 1977-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof IKZF1, IKZF2, BCL6 TSHR 3099/4885SLC1A3 2678/4885SLC1A2 2552/4885
US-12421251-B2 Cystic fibrosis transmembrane conductance regulator modulating agents CFTR, SCNN1G, CLCN2 TSHR 947/4885SLC1A3 795/4885SLC1A2 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.